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PROFESSIONALISM & COMMENTARY
Societal Economic Benefits Associated with an
Extended-Release Opioid with Abuse-Deterrent
Technology in the United States
Disclosure: This study was funded by Purdue Pharma
L.P. Dr. Ben-Joseph is an employee of Purdue Pharma
L.P.; Drs. Kirson, Shei, White, and Birnbaum are
employees of Analysis Group, Inc., a consulting firm
that received funding for this research from Purdue
Pharma L.P. Prof. Rossiter and Dr. Michna are
consultants on this project and received funding from
Analysis Group.
Common chronic pain conditions affect approximately
100 million U.S. adults and result in costs of $560–635
billion annually in direct medical treatment costs and lost
productivity [1]. In addition, pain is a common cause of
disability in the United States [2]. The Food and Drug
Administration (FDA) has noted that prescription opioids
(RxOs) are an important component of modern pain man-
agement [3]. At the same time, the agency has acknowl-
edged that RxO abuse is a serious public health problem.
The National Survey on Drug Use and Health (NSDUH)
reported that 1.8 million of the U.S. population ages 12
and up had prescription painkiller abuse or dependence in
2011 [4]. In 2007, RxO abuse accounted for an estimated
$55.7 billion (US$ 2009) in annual societal costs in the
United States [5]. These costs include health care, work-
place, and criminal justice costs.
Extended-release opioids (EROs) provide a longer period
of drug release and can thus be taken less frequently than
immediate-release opioids [6]. However, EROs can be
manipulated and tampered with in an attempt to over-
come their extended-release properties. Because of their
higher drug dosages, EROs may be more attractive to
some abusers than immediate-release formulations [7].
Manufacturers of EROs have attempted to address the
problem of RxO abuse by developing formulations with
abuse-deterrent properties. For example, reformulated
extended-release oxycodone HCl with abuse-deterrent
technology (reformulated ER oxycodone) was introduced
in August 2010 and replaced the original formulation of ER
oxycodone without abuse-deterrent technology. Several
studies have examined the impact of reformulated ER
oxycodone among abusers. A study on the attractiveness
of reformulated ER oxycodone relative to other opioid
formulations among recreational opioid abusers found
that reformulated ER oxycodone was rated the least
attractive, least valuable, least desirable, and least likely to
be tampered with among all the nonhypothetical opioid
products studied [8]. Another study of individuals being
treated for substance abuse found that abuse rates of
reformulated ER oxycodone were lower than historical
abuse for the original formulation of ER oxycodone [9].
In terms of the economic impact of reformulated ER
oxycodone, a recent paper by Rossiter et al. estimated
the impact of reformulated ER oxycodone by analyzing
real-world data following the introduction of reformulated
ER oxycodone [10]. Although there are other RxOs on the
market that use technologies designed to deter abuse, the
study focused on the launch of reformulated ER
oxycodone as it has gained substantial market share and
is currently the only RxO that has obtained FDA approval
with abuse-deterrent labeling [11]. The authors analyzed
de-identified administrative claims databases covering
over 56 million commercially insured beneficiaries and
approximately 31 million Medicaid enrollees [12] and
reported annual medical cost savings of $430 million (US$
2011) associated with reformulated ER oxycodone in the
United States [10].
These medical cost savings reported in Rossiter et al.
are an underestimate of the full societal economic ben-
efits of reformulated ER oxycodone, as RxO abuse is
also associated with higher rates of medical resource
utilization and costs among caregivers [13] and substan-
tial workplace and criminal justice costs [5]. Reformu-
lated ER oxycodone may reduce those abuse-related
costs as well. Building on prior research, the purpose of
this Commentary is to describe the results of an exten-
sion of the analysis reported in Rossiter et al. to estimate
the total annual cost savings associated with reformu-
lated ER oxycodone from a societal perspective, includ-
ing both direct medical cost savings and indirect cost
savings such as reduced caregiver burden and work-
place and criminal justice costs.
Rossiter et al. [10] estimated the annual abuse-related
medical cost savings of reformulated ER oxycodone by
analyzing changes in rates of diagnosed opioid abuse
associated with the introduction of reformulated ER
oxycodone and calculating the excess medical costs of
diagnosed opioid abuse in patient-level pharmacy and
medical claims data. The findings of their claims data
analyses were extrapolated to account for undiagnosed
abuse and to estimate annual medical cost savings at the
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U.S. population level. The study did not include estimates
of the indirect cost savings of reformulated ER oxycodone,
as such cost components are typically not directly observ-
able in claims data.
For the purposes of our calculations reported here, we
assumed that reformulated ER oxycodone would have the
same proportional effect on abuse-related indirect costs
as on abuse-related medical costs. We calculated the
percent reduction in abuse-related medical costs associ-
ated with reformulated ER oxycodone and applied this
same relative reduction to other cost components
reported in the literature to estimate the indirect cost
savings associated with reformulated ER oxycodone. The
percent reduction in abuse-related medical costs was cal-
culated by dividing the abuse-related medical cost savings
of reformulated ER oxycodone from Rossiter et al. [10] by
the excess medical and drug costs for opioid abuse
patients from Birnbaum et al. [5], which were adjusted
from US$ 2009 to US$ 2011 using the Consumer Price
Index (CPI). The CPI increased from 214.537 to 224.939
from 2009 to 2011 [14], representing an increase of
approximately 4.8%. The $430 million reduction in abuse-
related medical costs associated with reformulated ER
oxycodone amounted to 1.8% of the $24.2 billion in
excess medical and drug costs for opioid abuse patients
(see Table 1).
Birnbaum et al. [5] estimated abuse-related indirect
costs that included costs to the criminal justice system
and workplace costs (e.g., lost earnings, medically
related absenteeism, and disability claims). The authors
relied upon data from a number of different publicly avail-
able secondary sources (e.g., NSDUH, the Treatment
Episodes Data Set from the Substance Abuse and
Mental Health Services Administration, and the Bureau
of Justice Statistics) and applied either the quantity
method (i.e., multiplying the number of opioid abuse
patients by the cost per opioid patient) or the apportion-
ment method (i.e., apportioning the overall costs of drug
abuse based on the relative prevalence of RxO to overall
drug abuse) to estimate the societal indirect costs of
RxO abuse.
Of the $58.4 billion (US$ 2011; adjusted from $55.7 billion
[US$ 2009]) in annual societal costs of RxO abuse in the
United States, excess medical and drug costs for opioid
abuse patients accounted for $24.2 billion (41.4%), crimi-
nal justice costs accounted for $5.4 billion (9.2%), and lost
workplace productivity accounted for $26.8 billion (45.9%)
(see Table 1). Lost workplace productivity included pre-
mature death, lost wages/employment, excess medically
related absenteeism costs, excess disability costs, and
presenteeism costs. Additional costs included excess
medical and drug costs for caregivers of opioid abuse
Table 1 Medical and indirect cost savings associated with reformulated ER oxycodone
Cost Category
Cost of RxO
Abuse,
Millions*
Cost Savings
of Reformulated
ER Oxycodone,
Millions†
% Reduction
in Costs Due to
Reformulated
ER Oxycodone
Estimated Cost
Savings of
Reformulated
ER Oxycodone,
Millions‡
[A] [B] [C] = [B]/[A] [A] × [C]
Excess medical and drug costs for opioid abuse
patients, including substance abuse treatment
costs
$24,180 $ 430
1.8%
$430
Total criminal justice costs $5,391 $96
Lost workplace productivity
Premature death $11,762 $209
Lost wages/employment $10,169 $181
Excess medically related absenteeism costs $1,902 $34
Excess disability costs $846 $15
Presenteeism costs $2,143 $38
Excess medical and drug costs for caregivers of
opioid abuse patients
$1,868 $33
Prevention and research costs $161 Excluded
Total§ $58,424 $1,035
Notes:
* From Birnbaum et al. [5]; costs are measured in US$ 2011 (adjusted from US$ 2009 using CPI).
† From Rossiter et al. [10]; costs are measured in US$ 2011.
‡ Costs are measured in US$ 2011.
§ Figures have been rounded to the nearest million.
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patients, which accounted for $1.9 billion (3.2%), and
prevention and research costs, which accounted for $0.2
billion (0.3%).
Our estimates suggest societal benefits from reformu-
lated ER oxycodone. In addition to the annual abuse-
related medical cost savings of $430 million associated
with reformulated ER oxycodone [10], we estimated $96
million in cost savings to the criminal justice system (see
Table 1 and Figure 1). We estimated that reformulated
ER oxycodone was associated with cost savings of
$209 million for reductions in premature deaths (in terms
of lost earnings), $181 million for reductions in lost
wages and employment, $34 million for reductions in
excess medically related absenteeism costs, $15 million
in reductions in excess disability costs, and $38 million
for reductions in presenteeism costs, for a total of $476
million in workplace cost savings. Accounting for excess
medical and drug costs for caregivers of opioid abuse
patients resulted in additional annual cost savings of $33
million. Together, these indirect cost savings amounted
to annual societal indirect cost savings of $605 million. In
total, reformulated ER oxycodone was associated with
just over $1.0 billion in medical and indirect cost savings
per year in the United States. Although Birnbaum et al.
included estimates of the prevention and research costs
associated with RxO abuse, we did not include preven-
tion and research in our estimates of the societal cost
savings associated with reformulated ER oxycodone.
Prevention and research on RxO abuse are likely fixed
costs, and spending on prevention and research may
not decline with the introduction of reformulated ER
oxycodone, as the RxO market is dominated by RxOs
without abuse-deterrent properties. As noted above,
reformulated ER oxycodone is currently the only RxO
that has obtained FDA approval for abuse-deterrent
labeling.
Two prior studies estimated the potential societal impact
of hypothetical abuse-deterrent formulations (ADFs) of
RxOs. White et al. estimated potential annual health care
savings from a hypothetical ADF of $0.6–1.6 billion (US$
2006) in the United States in 2006 [15], whereas Skinner
estimated potential annual direct and indirect cost
savings of $0.5 billion (C$ 2011) in Canada in 2011 [16].
Both studies relied on assumed changes in rates of
opioid abuse and market share, so we consider our esti-
mate to be a more reliable estimate, as it builds on
observed real-world claims data after the introduction of
reformulated ER oxycodone, rather than a hypothetical
situation.
Our findings may represent a conservative estimate of the
annual societal cost savings associated with reformulated
ER oxycodone, as we did not attempt to account for
potential reductions in abuse-related mortality due to the
introduction of reformulated ER oxycodone. Our indirect
costs include lost productivity due to premature deaths, but
we do not estimate the economic costs of lives lost. Today,
RxOs account for more overdose deaths than heroin and
cocaine combined [17]. RxO abuse accounted for more
than 15,500 deaths in 2009, nearly a fourfold increase
compared with 1999 [18]. Further research is necessary to
establish the effect of reformulated ER oxycodone on
abuse-related mortality. Recent studies using an adverse
event reporting database have found reductions in the
number of fatal adverse events (including abuse and over-
dose) occurring after reformulated ER oxycodone was
introduced, as compared with the original formulation of ER
oxycodone without abuse-deterrent technology [19,20]. To
the extent that reformulated ER oxycodone contributes to
reduced mortality, the societal benefits associated with
reformulated ER oxycodone could be substantially higher
than those presented above. Furthermore, this study
focused on the economic benefits of reformulated ER
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Figure 1 Total annual societal
cost savings associated with
reformulated ER oxycodone.
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oxycodone, but there are likely additional benefits to
society (e.g., decreased emotional and financial burden on
family members) that are not quantified here.
As mentioned previously, this study focused on the impact
of reformulated ER oxycodone as it is the only ERO that has
received approval from the FDA for abuse-deterrent label-
ing to date [11], and it has garnered substantial market
share. In the future, as new ADFs enter the market and
obtain FDA approval for abuse-deterrent labeling, addi-
tional research should examine the impact of these ADFs.
Several study limitations are worth noting. This study
builds on a prior study that used an observational research
design, so caution is warranted in any causal interpreta-
tion of the findings. Rossiter et al. [10] observed changes
in medical costs and abuse rates associated with the
introduction of reformulated ER oxycodone, but it is pos-
sible that unobserved factors may have contributed to
these changes. In addition, the indirect cost savings asso-
ciated with reformulated ER oxycodone could not be
directly observed, so we relied on the assumption that
reformulated ER oxycodone had the same impact on
abuse-related indirect costs as it did on abuse-related
medical costs. In reality, reformulated ER oxycodone may
have had a greater impact on certain cost components
than on others. Although reformulated ER oxycodone has
been associated with reductions in medical costs and
rates of abuse, some serious abusers may switch to other
substances such as RxOs without abuse-deterrent prop-
erties or illicit drugs such as heroin [21–23].
In summary, this study estimated substantial annual soci-
etal cost savings associated with reformulated ER
oxycodone. Our calculations suggest that reformulated
ER oxycodone was associated with annual medical cost
savings of $430 million and indirect cost savings of $605
million, for total annual societal cost savings of approxi-
mately $1.0 billion. Although these cost savings are
sizable, they represent just 1.8% of the $58.4 billion (US$
2011) in overall societal costs of RxO abuse. Over time,
the societal cost savings associated with reductions in
abuse could increase as more RxOs with abuse-deterrent
properties are introduced. Reformulated ER oxycodone
represents one tool for addressing RxO abuse, but its
modest impact relative to the total societal costs of RxO
abuse suggests that other initiatives, such as greater edu-
cation of physicians and the identification and monitoring
of patients at high-risk of abuse, will be necessary to
further reduce the societal burden of RxO abuse.
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